V2-glycan/apex broadly neutralizing antibodies (bnAbs) recognize a closed quaternary structure of the HIV-1 envelope glycoprotein. He, Ou et al. introduced HCDR3 regions of neutralizing antibodies targeting this epitope into a diverse repertoire of murine B cell receptors (BCRs). Upon vaccination, these edited B cells affinity matured and generated potent neutralizing sera, highlighting the potential of an HCDR3-focused vaccine approach.
Tag: Immunodeficiency Disorders
[Viewpoint] Global HIV control: is the glass half empty or half full?
The massive scale-up of HIV treatment and prevention over the past two decades has resulted in important reductions in new infections and mortality globally . Reduction in HIV incidence has been unequal, however, with worsening epidemics in regions where the reach and scale of . HIV control programmes have been insufficient, especially in eastern Europe,… Continue reading [Viewpoint] Global HIV control: is the glass half empty or half full?
Emapalumab as bridge to hematopoietic cell transplant for STAT1 gain-of-function mutations
Asthma-protective agents in dust from traditional farm environments
Combined immunodeficiency and impaired PI3K signaling in a patient with biallelic LCP2 variants
Pregnancy in primary immunodeficiency diseases: The PREPI study
A new peptide may hold potential as an Alzheimer’s treatment
AI SummaryMIT neuroscientists have discovered a peptide that can reverse neurodegeneration and other symptoms of Alzheimer’s disease by interfering with an enzyme called CDK5 that is overactive in Alzheimer’s patients. In mice, the peptide led to reductions in neurodegeneration, DNA damage, and improvements in cognitive abilities, leading researchers to believe it could serve as a… Continue reading A new peptide may hold potential as an Alzheimer’s treatment